Correspondence on: 'Dupilumab as a novel steroid-sparing treatment for IgG₄-related disease' by Simpson et al

Ann Rheum Dis. 2022 Feb;81(2):e26. doi: 10.1136/annrheumdis-2020-217010. Epub 2020 Jan 29.

Authors

Mikael Ebbo^{1

2}, Benjamin De Sainte-Marie³, Romain Muller³, Christelle Piperoglou⁴, Aurélie Grados⁵, Frédéric Vély^{2

4}, Nicolas Schleinitz^{3

2}

Affiliations

¹ Internal Medicine, AP-HM, Hôpital de la Timone, Marseille, France mikael.ebbo@ap-hm.fr.
² Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.
³ Internal Medicine, AP-HM, Hôpital de la Timone, Marseille, France.
⁴ Immunology, AP-HM, Hôpital de la Timone, Marseille, France.
⁵ Internal Medicine, Centre hospitalier de Niort, Niort, France.

PMID: 31996366
DOI: 10.1136/annrheumdis-2020-217010

No abstract available

Keywords: DMARDs (biologic); T Cells; inflammation.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Humans
Immunoglobulin G
Immunoglobulin G4-Related Disease* / drug therapy
Steroids

Substances

Antibodies, Monoclonal, Humanized
Immunoglobulin G
Steroids
dupilumab